Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

LE Roeker, P Dreger, JR Brown, OB Lahoud… - Blood …, 2020 - ashpublications.org
Although novel agents (NAs) have improved outcomes for patients with chronic lymphocytic
leukemia (CLL), a subset will progress through all available NAs. Understanding outcomes …

Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post‐BCR inhibitor setting: a UK wide analysis

TA Eyre, AA Kirkwood, S Gohill… - British journal of …, 2019 - Wiley Online Library
Venetoclax is a BCL 2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic
leukaemia (CLL). We conducted a multi‐centre retrospective analysis of 105 R/R CLL …

The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia

TA Eyre, LE Roeker, CP Fox, SH Gohill… - British journal of …, 2020 - Wiley Online Library
Elderly chronic lymphocytic leukaemia (CLL) patients treated outside of trials have notably
greater toxicity with the Bruton's tyrosine kinase inhibitor ibrutinib compared to younger …

Results of a multicentre UK‐wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the …

TA Eyre, EH Phillips, KM Linton… - British journal of …, 2017 - Wiley Online Library
Relapsed or refractory classical Hodgkin lymphoma (cHL) is associated with a poor outcome
when standard chemotherapy fails. Brentuximab vedotin (BV) is an anti‐CD 30 monoclonal …

Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma

TA Eyre, WL Osborne, E Gallop-Evans… - British journal of …, 2018 - ueaeprints.uea.ac.uk
13. Department of Haematology, St George’s Hospital, Blackshaw Rd, Tooting, London SW17
0QT Title Page Results of a multicentr Page 1 24 13. Department of Haematology, St George’s …

[HTML][HTML] Risk-stratified sequential treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for de-novo post-transplant lymphoproliferative disorder: results of the tidal …

S Chaganti, S Maycock, G McIlroy, WA Iqbal, J Mason… - Blood, 2021 - Elsevier
Introduction Post-transplant lymphoproliferative disease (PTLD) is a rare and life-threatening
complication of solid organ transplantation (SOT). Most are of B-cell origin and treated with …

Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T‐cell depletion and deletion of chromosome 17p

A Arumainathan, N Kalakonda… - European Journal of …, 2011 - Wiley Online Library
Lenalidomide is an immunomodulatory agent with activity in a range of haematological
cancers including chronic lymphocytic leukaemia (CLL). However, major questions remain …

Lymphoma

R Sammut, A Arumainathan - InnovAiT, 2013 - journals.sagepub.com
Lymphomas are a diverse group of malignant disorders of lymph nodes, extranodal organs
and the bone marrow. Lymphomas can broadly be divided into Hodgkin and non-Hodgkin …

[HTML][HTML] Allogeneic stem cell transplantation (alloHSCT) for chronic lymphocytic leukemia (CLL) in the era of novel agents

LE Roeker, JR Brown, P Dreger, OB Lahoud, TA Eyre… - Blood, 2019 - Elsevier
Introduction: Prior to effective novel agent (NA) approval for CLL, alloHSCT was
recommended for CLL patients (pts) with early relapse/refractory disease after purine …

A rare cause of weight loss

PK Flanagan, SE Coupland, A Arumainathan… - Gut, 2014 - gut.bmj.com
A 36-year-old man of Eastern European origin presented with a 4-week history of
odynophagia, dysphagia, 10kg weight loss and night sweats. There was no significant past …